Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JAK3 inhibitor (Guangzhou Nanxin Pharmaceutical)
- Development stage
- Preclinical
- Lead developer
- Guangzhou Nanxin Pharmaceutical
- Modality
- Small Molecules
01
Overview
JAK3 inhibitor (Guangzhou Nanxin Pharmaceutical) is a small-molecule inhibitor of Janus kinase 3 (JAK3) and TEC family kinases currently in preclinical development. Developed by Guangzhou Nanxin Pharmaceutical, it is being investigated for the treatment of various autoimmune and inflammatory conditions, including rheumatoid arthritis, Crohn's disease, vitiligo, ulcerative colitis, and alopecia. By targeting JAK3, the drug blocks the signaling of cytokines that share the common gamma chain receptor subunit, such as IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21, which are vital for T-cell and NK-cell function. The additional inhibition of TEC family kinases may further modulate B-cell and T-cell receptor signaling, potentially offering a differentiated therapeutic profile for immune-mediated diseases.
- Other names
- JAK3抑制剂JAK3/TEC inhibitor
02
Targets
JAK3 (Janus kinase 3)TEC family (TEC family tyrosine kinases)
Beyond the preview
Go deeper on JAK3 inhibitor (Guangzhou Nanxin Pharmaceutical).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JAK3 inhibitor (Guangzhou Nanxin Pharmaceutical).